exploitation of this strategy. Several steps are needed in order to increase the proportion of patients who benefit from immunotherapies.We currently do not understand completly the reason why an immune response could be efficient or not (spontaneously or after treatment), the respective role and interactions between humoral and cellular responses and mechanisms involved in the development of side effects observed in patients Method: All NSCLC patients who are candidate for Immunotherapy treatment regardless of staging and line of treatment cancer will be identified within our oncology department Blood sampling will be performed (50 to 100 ml) at severals time points: before any immunotherapy and repeated every 3 months or, in case of side effects or in case of extra-ordinary evolution. We will investigate cellular (T lymphocytes) and humoral (B lymphocytes) immune responses. We will also do a sequencing of the tumor in order to investigate genetic alterations. We will question the correlations between immune response and tumor pathological and molecular characteristic's, as well as the impact of therapies administered to the patients on their immune response. Result: We have recruited 12 patients so far, on treatment with immune check point inhibitor. We are going to perform another sampling 3 months after the beginning of the treatment (9 patients at the present time) Currently, we are continuing to reclute patients. The first analysis will be performed once we have 50 patients within the study and presented and the incoming meeting in November 2018 Conclusion: This is, as far as we know, the first prospectiveand ongoing immune-bio-bank in NSCLC patients that is going to provide valuable information to better understand the immunological changing at serological, tissue and genomic level induced by the immunotherapy in NSCLC and the possible mechanism of resistance or progression.
exploitation of this strategy. Several steps are needed in order to increase the proportion of patients who benefit from immunotherapies.We currently do not understand completly the reason why an immune response could be efficient or not (spontaneously or after treatment), the respective role and interactions between humoral and cellular responses and mechanisms involved in the development of side effects observed in patients Method: All NSCLC patients who are candidate for Immunotherapy treatment regardless of staging and line of treatment cancer will be identified within our oncology department Blood sampling will be performed (50 to 100 ml) at severals time points: before any immunotherapy and repeated every 3 months or, in case of side effects or in case of extra-ordinary evolution. We will investigate cellular (T lymphocytes) and humoral (B lymphocytes) immune responses. We will also do a sequencing of the tumor in order to investigate genetic alterations. We will question the correlations between immune response and tumor pathological and molecular characteristic's, as well as the impact of therapies administered to the patients on their immune response. Result: We have recruited 12 patients so far, on treatment with immune check point inhibitor. We are going to perform another sampling 3 months after the beginning of the treatment (9 patients at the present time) Currently, we are continuing to reclute patients. The first analysis will be performed once we have 50 patients within the study and presented and the incoming meeting in November 2018 Conclusion: This is, as far as we know, the first prospectiveand ongoing immune-bio-bank in NSCLC patients that is going to provide valuable information to better understand the immunological changing at serological, tissue and genomic level induced by the immunotherapy in NSCLC and the possible mechanism of resistance or progression. Keywords: biobank, immunotherapies, Immunomodulation P1.04-27 Safety of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) in the Real-Life Setting: A Single-Institution Experience from Argentina M. Bluthgen, 1 M. Tamburelli, 2 C. Calderon, 2 J. Castillo, 2 C. Bas, 2 G. Gomez Abuin, 2 S. Sena 1 1 Thoracic Oncology, Hospital Aleman, Buenos Aires/AR, 2 Oncology, Hospital Aleman, Buenos Aires/AR Background: Immunotherapy (IO) targeting programmed death-1 receptor (PD-1) has become standard of care in NSCLC treatment. Therefore, many patients will be at risk of developing toxicities from these treatments, representing a new challenge in daily clinical practice. We assessed its safety and activity in advanced NSCLC patients in the real-life setting. Method: We conducted a retrospective analysis of patients with NSCLC treated with immunotherapy at a single institution between January 2016 and January 2018. Safety and efficacy analyses were made by treating physician according to CTCEAE 4.0 and RECIST 1.1 respectively and retrospectively collected from medical records. Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Result: Twenty-seven patients were included. Median age was 66 years [range 45 -79], 67% were male, 89% (n¼24) had ECOG performance status (PS) of 0-1; all patients had advanced disease, with up to 2 metastatic sites in 52% (n¼14) of the cases; 45% (n¼12) had been tested and were positive for PDL-1 ( 1%). Almost all patients received immunotherapy as first or second-line treatment (n¼ 23, 85%). A median of 6 cycles [range 1 e 34] had been administered, with 60% exposed to nivolumab (n¼16) and 40% (n¼11) to pembrolizumab. Median follow-up since IO was 18 months [range 0.5 -25.2]. Seven patients achieved partial response and eight had stable disease, giving an overall response rate of 26% and a 56% disease control rate; 44% presented progressive disease. Median PFS was 5.1 months [95%CI 2 e 8.1] and median OS was 19.3 months [95%CI 2.3 e 36.3]. A total of 10 patients (37%) developed high grade toxicity. The most common grade 3-4 related events were asthenia (n¼5), adrenal insufficiency (n¼2), infection (n¼2), hypothyroidism (n¼1), hepatitis (n¼1), renal insufficiency (n¼1) and thrombocytopenia (n¼1) among others. Seven patients should discontinue treatment, 5 of them received glucocorticoids and almost all of them had full recovered after corticoid treatment (n¼5). Conclusion: Activity of immunotherapy was comparable to that reported in previous studies. However, high grade toxicity rates in our practice were much higher than those reported in clinical trials, despite the highly similar proportion of patients with good performance status in both settings. Although studies populations are highly selected, this finding must lead us to question our ability in early recognition and prompt management of adverse events in daily practice. Background: Nivolumab is a novel therapeutic option in pre-treated Non Small Cell Lung Cancer(NSCLC), independently of tumor histology and PD-L1 status. However, predictive biomarkers are lacking. We aimed to evaluate whether there is a correlation between some baseline markers of inflammation and the outcome of patients (pts) treated with Nivolumab. Method: All consecutive NSCLC pts treated with Nivolumab between Aug. 2015-Dec. 2017 at our Institution were analyzed. Baseline characteristics were collected and correlated with the outcome. Derived neutrophil-to-lymphocyte (dNLR) ratio was calculated as: neutrophil count/white blood count e neutrophil count. Platelet-to-lymphocyte (PLR) ratio was defined as platelet count/ lymphocyte count. Overall survival (OS) was defined as time from Nivolumab start to death and Progression Free Survival (PFS) as time from Nivolumab start to progression disease or death for any cause. OS and PFS survival were estimated using the KaplaneMeier method. Survival curves were compared using the log-rank test. Result: We included 45 consecutive NSCLC pts treated with Nivolumab. Baseline characteristics were as follows: median age 69 years (range 46-78), sex male 78%, female 12%, squamous histology in 51% and non-squamous in 49%. After a median follow-up of 16 months (mos), median PFS was 4.0 mos (CI 95%, 2-8) and median OS was 9.0 mos (CI 95%, 4-15). High neutrophil count (7500/mmc) and high lymphocyte count (1000/ mmc) were associated with a shorter PFS (p¼0.05 and p¼0.01, respectively) and OS (p¼0.373 and p<0.001, respectively), as well as low albumin levels (<3 g/dl) (p¼0.05 for both PFS and OS). Moreover, a high dNLR (3), high PLR (160) and high LDH levels (> Upper Limit Normal) correlated with a numerically longer PFS and OS, although these differences were not statistically significant. Conclusion: Baseline markers of inflammation correlate with inferior outcome with Nivolumab in unselected, pretreated, NSCLCs. The relative easy estimation of these parameters may be used with other predictive biomarkers in the treatment selection of pts candidate for immunotherapy. Keywords: PLR, dNLR, Nivolumab
